SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-067379
Filing Date
2020-05-29
Accepted
2020-05-29 09:01:30
Documents
2
Period of Report
2020-05-29
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2019110-3_8k.htm 8-K 22932
2 EXHIBIT 99.1 tm2019110d3_ex99-1.htm EX-99.1 17448
  Complete submission text file 0001104659-20-067379.txt   41567
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 20924204
SIC: 2834 Pharmaceutical Preparations